PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

More Democrats Express Alarm Over House Leadership’s Bid to Overturn Iowa Election Results

Show Me

New Election Lawsuits

Show Me

Trump Lauds Georgia Republicans for Enacting Election Reforms

Show Me

Michigan GOP claims they can sidestep Gov Whitmer and ensure ‘fair, safe, and open’ elections in 2022 (Video)

Show Me

Zuckerberg’s Election Rigging Group Sends VP to Be Biden’s Tech Director.

Show Me

Ontario Superior Court Strikes Down Election Law Restricting Free Speech

Show Me

Sullivan Vows Murkowski Election Support Despite Trump Challenge

Show Me

Leftists Target Georgia for Boycotts After Election Integrity Law Passed

Show Me

Graham Accuses Biden of Playing ‘Race Card’ Over Georgia Election Reform Law

Show Me

Amazon Union Election Set to Conclude: What We Know

Show Me

California’s election rules could make a Newsom recall a wild ride

Show Me

Wisconsin to investigate 2020 election

Show Me

Group Sues Congress, Seeks New Presidential Election (Video)

Show Me

Georgia passes election integrity law

Show Me

Manchin says Democrat-led election-reform bills will go nowhere without bipartisan support

Show Me

Judicial Watch at the Supreme Court: Fighting for Clean Elections

Show Me

Election Audit Reveals Irregularities for 1 in 14 Mail-In Votes Cast.

Show Me

Georgia Legislator Pushes Back On CNN Host’s Criticisms And ‘False Narrative’ Surrounding Georgia Election Bill

Show Me

(NEW) Donald Trump website: 45office.com

Show Me

Woody Allen on Dylan Farrow’s accusation: ‘I believe she believes that’

Show Me

Just who is it attacking Asian Americans?

Show Me

Asians Rarely, Though Increasingly Face Hate Crimes

Show Me

Massage Parlors Attacked by Gunman Busted in Prostitution Stings

Show Me

Atlanta Shooting Suspect Charged with ‘Malice Murder’ and Aggravated Assault

Show Me

Suspected Atlanta gunman Robert Aaron Long had been to spas before

Show Me

Atlanta shooting suspect said killing of Asian women wasn’t racially motivated, blames sex addiction

Show Me

Elizabeth Warren Calls Filibuster Racist Months After Filibustering Tim Scott Police Reform Bill

Show Me

‘Marrying my husband made me realise I was racist’: Harry and Meghan’s new strategist says

Show Me

Evanston, Illinois, to Pay Reparations to Black Families Harmed by Decades of Racist Housing Policies

Show Me

Sen. Tim Scott Hammers Democrat Hypocrisy Using ‘Racist’ Filibuster Against Him

Show Me

REPORT: Investigation Clears Cafeteria Worker At Elite College Smeared As Racist By Student, But Now She Has Trouble Finding A Job

Show Me

PIERS MORGAN: I’m not a racist and neither is Sharon Osbourne but that didn’t stop the woke mob lynching her

Show Me

Gina Carano Responds To Former Senator Heidi Heitkamp Calling Her A ‘Nazi’ On ‘Real Time With Bill Maher’

Show Me

GOP congressman: It’s racist to suggest voter ID requirements hinder African-Americans

Show Me

Facts Matter (March 29): Heavily Armed Antifa Rioters Stormed Oregon Capital

Show Me

Protesters, National Guard spar over locks on fence outside Chauvin courthouse

Show Me

Former Officer’s Trial in George Floyd’s Death Begins

Show Me

Commentary: Movement Grows to Recall Progressive District Attorneys

Show Me

Defiant Michigan Restaurant Owner Jailed After Appearing On Tucker Carlson Show

Show Me

Carlson: They want you to know that defiance is the real crime

Show Me